Aurora Cannabis (TSX:ACB) Gains on Record Adjusted EBITDA

Highlights

• Record adjusted EBITDA reported for the fiscal year with strong European medical cannabis performance.
• Medical cannabis products expanded across Canada, Europe, and Australia.
• Annual General Meeting scheduled for August following fiscal year results.

Aurora Cannabis reported record adjusted EBITDA, expanded medical cannabis products internationally, and strengthened global operations while remaining part of the S&P/TSX Composite Index sector.

Aurora Cannabis (TSX:ACB) operates within the cannabis sector, focusing primarily on medical cannabis cultivation, manufacturing, and distribution across multiple international markets. As a constituent associated with the S&P/TSX Composite Index, the company remains part of Canada's regulated cannabis industry while expanding its presence through medical cannabis operations in Europe, Australia, and Canada. The business continues to emphasize pharmaceutical-grade production standards, product diversification, and international distribution supported by regulatory approvals.

Record Adjusted EBITDA Reflects Operational Performance

The latest fiscal year results highlighted record adjusted EBITDA, reflecting continued operational improvements alongside expanding medical cannabis sales. European medical cannabis operations recorded double-digit year-over-year growth, contributing significantly to overall business performance. Demand across regulated medical markets continued to support sales volumes while operational efficiencies strengthened overall business activity.

Medical cannabis has become an increasingly important segment within the company's operations, supported by pharmaceutical distribution channels and healthcare partnerships across several jurisdictions. Continued cultivation improvements, manufacturing capabilities, and standardized production processes have enabled supply across multiple regulated markets.

International Medical Cannabis Operations

Europe remains one of the company's largest international regions, with medical cannabis distributed through established healthcare systems in countries including Germany and Poland. Regulatory compliance, pharmaceutical manufacturing standards, and certified cultivation facilities continue to support product availability throughout these markets.

Australia also represents an established medical cannabis destination, where product availability has expanded alongside growing physician participation in regulated prescribing programs. International operations continue to complement domestic activities while broadening geographic diversification.

Within the broader Cannabis Stocks category, international medical markets have become an increasingly important component of business activity for licensed Canadian producers operating under pharmaceutical standards.

Product Portfolio Expansion

Recent product launches included dried flower, pre-rolls, and cannabis pastilles across Canada, Europe, and Australia. These additions broaden available treatment formats for healthcare providers and registered patients while addressing varying regulatory requirements across different jurisdictions.

Dried flower products remain widely prescribed in several medical cannabis programs, while pre-roll formats provide additional convenience where permitted. Cannabis pastilles offer a non-inhalation alternative designed for measured dosing within regulated medical frameworks.

Product development continues to focus on consistency, standardized cannabinoid content, and compliance with pharmaceutical manufacturing requirements. Each regional market maintains distinct packaging, formulation, and regulatory standards, requiring tailored product development before commercial distribution.

Canadian Operations

Canadian operations continue to support cultivation, product development, manufacturing, and distribution activities. Domestic medical cannabis programs provide an established platform for introducing new formulations before broader international availability where regulations permit.

Production facilities maintain quality assurance systems designed to satisfy both Canadian requirements and international export standards. Manufacturing capabilities include cultivation, harvesting, processing, packaging, laboratory testing, and distribution within regulated supply chains.

Operations across Canada also contribute to research initiatives involving genetics, cultivation methods, cannabinoid formulations, and product consistency. These activities support long-term product availability across both domestic and international markets.

Global Distribution Network

International exports remain an important component of business operations. Medical cannabis products are supplied through licensed importers, pharmaceutical distributors, healthcare providers, and regulated pharmacy networks depending on local market requirements.

Export activities require compliance with international treaties, Good Manufacturing Practice certification, and country-specific licensing processes. Distribution networks have expanded gradually as additional jurisdictions introduce or broaden regulated medical cannabis frameworks.

As activity within the S&P/TSX Composite Index continues to reflect a broad range of Canadian industries, regulated cannabis businesses remain a distinct component of the healthcare-related segment represented on the exchange.

Annual General Meeting and Corporate Activities

The company has scheduled its Annual General Meeting for August following publication of fiscal year financial results during June. The meeting forms part of regular corporate governance activities and provides updates regarding operational developments, business activities, and corporate matters.

Public disclosures during the fiscal year also highlighted continued emphasis on medical cannabis, international distribution, product innovation, and operational efficiency. Expansion across Europe and Australia remains aligned with licensed medical cannabis programs supported by healthcare professionals and regulated pharmaceutical channels.

Medical cannabis continues to represent the central business focus while recreational cannabis products remain available within Canada's regulated marketplace. International diversification has gradually expanded the company's geographic footprint beyond the domestic market through licensed exports and pharmaceutical partnerships.

The combination of regulated cultivation, manufacturing, research, product development, and international distribution continues to define the operations of Aurora Cannabis (TSX:ACB). Activity across Canada, Europe, and Australia demonstrates ongoing participation in regulated medical cannabis markets while maintaining compliance with evolving healthcare and pharmaceutical standards. Continued product launches and international expansion reinforce the company's position within the S&P/TSX Composite Index and the Canadian cannabis industry. Aurora Cannabis remains focused on regulated medical cannabis production and global distribution across approved healthcare markets.